CAR-T Cell Therapy Approval Status for Second-Line DLBCL
Yes, CAR-T cell therapy is now FDA-approved for second-line treatment of diffuse large B-cell lymphoma in patients who are refractory to first-line chemoimmunotherapy or who relapse within 12 months of first-line treatment. 1
Current FDA-Approved Indications for DLBCL
The FDA has approved CAR-T therapy (lisocabtagene maraleucel/BREYANZI) for adult patients with large B-cell lymphoma including DLBCL in three distinct clinical scenarios 1:
Second-line setting (early relapse/refractory): Patients with refractory disease to first-line chemoimmunotherapy OR relapse within 12 months of first-line chemoimmunotherapy 1
Second-line setting (transplant-ineligible): Patients with refractory disease to first-line chemoimmunotherapy OR relapse after first-line chemoimmunotherapy who are not eligible for hematopoietic stem cell transplantation due to comorbidities or age 1
Third-line and beyond: Patients with relapsed or refractory disease after 2 or more lines of systemic therapy 1
Evolution from Third-Line to Second-Line Approval
This represents a significant shift from the original 2019 approval landscape. Historical NCCN guidelines from 2019 restricted CAR-T therapy to patients who had received ≥2 prior chemoimmunotherapy regimens 2, effectively making it a third-line or later option. The current FDA approval now explicitly includes second-line use for specific high-risk populations 1.
Clinical Evidence Supporting Second-Line Use
The European Society for Medical Oncology recognizes that CAR-T therapy demonstrates superior outcomes compared to the traditional autologous stem cell transplantation pathway in early relapsed disease 3. For patients who relapse within 12 months of rituximab-containing first-line therapy, the traditional ASCT pathway yields only 23% three-year progression-free survival 3. CAR-T is now considered equivalent or superior to ASCT based on recent evidence 3.
Key Eligibility Criteria
Patients being considered for second-line CAR-T therapy must meet specific organ function requirements 3:
Critical Clinical Decision Point
Do not proceed directly to autologous stem cell transplantation without first considering CAR-T therapy in patients with early relapsed or refractory DLBCL, as the evidence now favors CAR-T in this population 3. The traditional salvage chemotherapy followed by ASCT pathway should be reserved for patients who do not meet criteria for second-line CAR-T or who are not candidates for cellular therapy 3.
Important Limitation
CAR-T therapy is not indicated for primary central nervous system lymphoma 1. This is a critical exclusion, as primary CNS DLBCL requires fundamentally different treatment approaches with high-dose methotrexate-based regimens 4.